<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asxannounc050913.txt
<TEXT>
UNITED STATES
SECURITIES	AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September2005

Novogen Limited
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes   No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
	82- ________________	.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 13 September, 2005  By /s/Ronald Lea Erratt Company Secretary

ASX & MEDIA RELEASE
13 SEPTEMBER 2005

NOVOGEN LIMITED ANNOUNCES ITS INTENTION TO LIST GLYCOTEX INC ON
THE NASDAQ NATIONAL MARKET


Pharmaceutical company Novogen Limited announced today that
Glycotex, Inc., its US subsidiary, filed a registration statement
with the Securities Exchange Commission for an initial public
offering of its common stock units, each unit consisting of one
share of Glycotex common stock and one warrant to purchase one
share of Glycotex common stock.

Janney Montgomery Scott LLC will be the underwriter.  When available,
a preliminary prospectus relating to these securities may be obtained
from Janney Montgomery Scott LLC, at 1801 Market Street, Philadelphia,
Pennsylvania 19103.

A registration statement relating to these securities has been
filed with the Securities Exchange Commission but has not yet become
effective.  These securities may not be sold nor may any offer to buy
be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state.

Glycotex, Inc. is a clinical stage biopharmaceutical company focused
on discovering and developing a novel class of drugs for human wound
healing and tissue repair.

Novogen (Nasdaq: NVGN  ASX: NRT) is a world leader in the research and
development of drugs derived from its phenolic technology platform.
The Company manages its international research and development
programs using the expertise and clinical research capabilities
of universities and hospitals in the US, Australia and other key
international locations.  The oncology compound phenoxodiol is being
developed by the Company's listed subsidiary
Marshall Edwards Inc. (Nasdaq: MSHL).


Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials.  After the results of these trials
are submitted in a new drug application to the FDA, the FDA must
approve the drug as safe and effective before marketing can take place.

Statements included in this press release that are not historical
in nature are "forward-looking statements" within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are subject
to a number of risks and uncertainties, including, but not limited to,
our failure to successfully commercialize our product candidates;
costs and delays in the development and/or FDA approval,
or the failure to obtain such approval, of our product candidates;
uncertainties in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our dependence upon,
collaboration or contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution of
any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the patents
and proprietary rights of others; general economic conditions;
the failure of any products to gain market acceptance; our inability
to obtain any additional required financing; technological changes;
government regulation; changes in industry practice; and
one-time events. We do not intend to update any of these factors
or to publicly announce the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Novogen Limited, + 61.2.9878 0088
</TEXT>
</DOCUMENT>
